Abstract Library

#4629 Identification of putative master regulators in pancreatic neuroendocrine tumours using gene expression data and network inference

Introduction: Pancreatic neuroendocrine tumours (pNETs) are a heterogenous group of pancreatic malignancies with a unique biology and pathophysiology. Tumour grade and extension are commonly used for prognostic determination. Current pathologic grading system needs regular updates to refine prognostic classification. Genomic screening may provide more objective classes and reflect tumour biology.

Conference:

Presenting Author: Jannin A

Authors: Jannin A, Elati M, Do Cao C, Figeac M, Leteurtre E,

Keywords: pancreatic neuroendocrine tumour, RNA-Seq, Master regulators, MEN1,

#4575 Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Safety and exploratory efficacy results from a phase II, randomised, parallel-group study

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for the treatment of carcinoid syndrome (CS).

Conference:

Presenting Author: Hajac L

Authors: Hajac L, Chauhan A, Mohamed A, Usiskin K, Mui C,

Keywords: paltusotine, phase 2 trial, somatostatin receptor agonist, safety, carcinoid syndrome,

#4462 Clustering of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) using machine learning (ML) and comparison with tumour, node, metastasis (TNM) staging: A population-based study using surveillance, epidemiology, and end results (SEER)

Introduction: TNM 8 is the staging system for GEP-NEN, guiding prognosis and treatment. However, it does not include important prognostic factors such as age, sex, race, and morphology.

Conference:

Presenting Author: Mortagy M

Authors: Mortagy M, El Asmar M, White B, Chandrakumaran K, Ramage J,

Keywords: Clustering, Machine learning, GEP-NEN, TNM Staging, Survival Analysis, SEER,

#4461 Systemic anti-cancer therapy in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC): Insights from National Cancer Registration and Analysis Service (NCRAS)

Introduction: ENETS advocates the use of platinum-based chemotherapy in combination with Etoposide as first-line chemotherapy in advanced GEP-NEC. Available retrospective evidence is from small studies.

Conference:

Presenting Author: Mortagy M

Authors: Mortagy M, El Asmar M, Paisey S, White B, Chandrakumaran K,

Keywords: Systemic anti-cancer therapy, Chemotherapy, GEP-NEC, NCRAS,

#4458 Survival and optimal follow-up cut-off of lung neuroendocrine tumours after surgery: Experience of a high-volume centre over 25 years

Introduction: Surgery is the curative therapy for lung neuroendocrine tumours (NET). Follow-up protocols after surgery are not evidence based and factors affecting survival are not clear.

Conference:

Presenting Author: Mortagy M

Authors: Mortagy M, El Asmar M, Nonaka D, Dolly S, Srirajaskanthan R,

Keywords: Lung NET, Lung NET Surgery, Follow-up after surgery,